NasdaqCM:ADMA

Stock Analysis Report

Executive Summary

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.

Share Price & News

How has ADMA Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

6.2%

NasdaqCM:ADMA

1.5%

US Biotechs

0.9%

US Market


1 Year Return

-27.4%

NasdaqCM:ADMA

-7.3%

US Biotechs

0.3%

US Market

ADMA underperformed the Biotechs industry which returned -8% over the past year.

ADMA underperformed the Market in United States of America which returned -0.5% over the past year.


Share holder returns

ADMAIndustryMarket
7 Day6.2%1.5%0.9%
30 Day5.4%2.2%-1.9%
90 Day-12.8%3.5%1.6%
1 Year-27.4%-27.4%-6.5%-7.3%2.6%0.3%
3 Year-26.9%-26.9%8.9%5.2%41.0%31.8%
5 Year-56.2%-56.2%6.6%1.6%55.2%38.0%

Price Volatility Vs. Market

How volatile is ADMA Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ADMA Biologics undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

ADMA Biologics's share price is below the future cash flow value, and at a moderate discount (> 20%).

ADMA Biologics's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

ADMA Biologics is loss making, we can't compare its value to the US Biotechs industry average.

ADMA Biologics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for ADMA Biologics, we can't assess if its growth is good value.


Price Based on Value of Assets

ADMA Biologics is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is ADMA Biologics expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

70.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

ADMA Biologics's revenue is expected to grow significantly at over 20% yearly.

ADMA Biologics's earnings are expected to grow significantly at over 20% yearly.

ADMA Biologics's revenue growth is expected to exceed the United States of America market average.

ADMA Biologics's earnings growth is expected to exceed the United States of America market average.

ADMA Biologics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if ADMA Biologics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has ADMA Biologics performed over the past 5 years?

-34.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

ADMA Biologics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare ADMA Biologics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare ADMA Biologics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if ADMA Biologics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if ADMA Biologics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if ADMA Biologics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is ADMA Biologics's financial position?


Financial Position Analysis

ADMA Biologics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

ADMA Biologics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

ADMA Biologics's level of debt (175.6%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (79.7% vs 175.6% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

ADMA Biologics has sufficient cash runway for 1.1 years based on current free cash flow.

ADMA Biologics has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 49.8% each year.


Next Steps

Dividend

What is ADMA Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate ADMA Biologics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate ADMA Biologics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as ADMA Biologics has not reported any payouts.

Unable to verify if ADMA Biologics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as ADMA Biologics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of ADMA Biologics's salary, the management and board of directors tenure and is there insider trading?

7.2yrs

Average management tenure


CEO

Adam Grossman (42yo)

7.8yrs

Tenure

US$1,553,300

Compensation

Mr. Adam S. Grossman is the Co-Founder of ADMA Biologics, Inc. and has been its Chief Executive Officer and President since October 2011 and 2007 respectively. Mr. Grossman serves as the President, Chief E ...


CEO Compensation Analysis

Adam's remuneration is higher than average for companies of similar size in United States of America.

Adam's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

7.2yrs

Average Tenure

59yo

Average Age

The average tenure for the ADMA Biologics management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

7.3yrs

Average Tenure

56yo

Average Age

The tenure for the ADMA Biologics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$21,802,32807 Jun 19
Biotest Divestiture Trust
EntityCompany
Shares5,813,954
Max PriceUS$3.75
BuyUS$16,000,00023 May 19
Perceptive Advisors LLC
EntityCompany
Shares4,000,000
Max PriceUS$4.00
BuyUS$100,00021 May 19
Lawrence Guiheen
EntityIndividual
Role
Member of the Board of Directors
Director
Shares25,000
Max PriceUS$4.00
BuyUS$48,00021 May 19
Jerrold Grossman
EntityIndividual
Role
Vice Chairman
Co-Founder & Vice Chairman
Shares12,000
Max PriceUS$4.00
BuyUS$18,00021 May 19
James Mond
EntityIndividual
Role
Chief Scientific Officer
Executive VP
Shares4,500
Max PriceUS$4.00
BuyUS$20,00021 May 19
Brian Lenz
EntityIndividual
Role
Chief Financial Officer
Executive VP & CFO
Shares5,000
Max PriceUS$4.00
BuyUS$120,00021 May 19
Adam Grossman
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares30,000
Max PriceUS$4.00

Ownership Breakdown


Management Team

  • James Mond (73yo)

    Executive VP

    • Tenure: 7.1yrs
    • Compensation: US$1.05m
  • Brian Lenz (47yo)

    Executive VP & CFO

    • Tenure: 7.3yrs
    • Compensation: US$940.09k
  • Jerrold Grossman (71yo)

    Co-Founder & Vice Chairman

    • Tenure: 7.8yrs
    • Compensation: US$111.15k
  • Adam Grossman (42yo)

    Co-Founder

    • Tenure: 7.8yrs
    • Compensation: US$1.55m
  • James Hauert

    Senior Vice President of Commercialization & Strategy

    • Tenure: 4.1yrs

Board Members

  • Bryant Fong (46yo)

    Director

    • Tenure: 7.3yrs
    • Compensation: US$97.76k
  • Dov Goldstein (52yo)

    Director

    • Tenure: 12.6yrs
    • Compensation: US$90.55k
  • Eric Richman (58yo)

    Director

    • Tenure: 12.6yrs
    • Compensation: US$104.97k
  • Steve Elms (56yo)

    Chairman of the Board

    • Tenure: 0.0yrs
    • Compensation: US$111.15k
  • Jerrold Grossman (71yo)

    Co-Founder & Vice Chairman

    • Tenure: 7.8yrs
    • Compensation: US$111.15k
  • Adam Grossman (42yo)

    Co-Founder

    • Tenure: 7.8yrs
    • Compensation: US$1.55m
  • Larry Guiheen (68yo)

    Director

    • Tenure: 7.1yrs
    • Compensation: US$98.79k
  • John DeVincenzo

    Member of Scientific Advisory Board

    • Tenure: 5.2yrs
  • Roy Chemaly

    Member of Scientific Advisory Board

    • Tenure: 5.2yrs
  • Jordan Orange

    Member of Scientific Advisory Board

    • Tenure: 5.2yrs

Company Information

ADMA Biologics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ADMA Biologics, Inc.
  • Ticker: ADMA
  • Exchange: NasdaqCM
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$243.203m
  • Shares outstanding: 59.32m
  • Website: https://www.admabiologics.com

Number of Employees


Location

  • ADMA Biologics, Inc.
  • 465 State Route 17
  • Ramsey
  • New Jersey
  • 7446
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ADMANasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDOct 2013

Biography

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectiou ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 00:36
End of Day Share Price2019/08/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.